The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy?
The mechanistic target of rapamycin (mTOR) is part of the phosphoinositide-3-kinase (PI3K)/protein kinase B (AkT)/mTOR pathway and owes its name to the inhibitory effect of rapamycin. The mTOR has a central converging role for many cell functions, serving as a sensor for extracellular signals from e...
Main Authors: | Giuseppe Lamberti, Nicole Brighi, Ilaria Maggio, Lisa Manuzzi, Chiara Peterle, Valentina Ambrosini, Claudio Ricci, Riccardo Casadei, Davide Campana |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-03-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/19/3/747 |
Similar Items
-
Low Grade Neuroendocrine Tumors of the Lung
by: Barbara Melosky
Published: (2017-06-01) -
Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study
by: Yao JC, et al.
Published: (2019-02-01) -
Management of Small Bowel Neuroendocrine Tumors
by: Vincent Larouche, et al.
Published: (2019-09-01) -
Aggressive neuroendocrine tumor of the ovary with multiple metastases treated with everolimus: A case report
by: Michiko Kaiho-Sakuma, et al.
Published: (2018-02-01) -
Emerging use of everolimus in the treatment of neuroendocrine tumors
by: Gajate P, et al.
Published: (2017-06-01)